Sutro Biopharma has signed a collaboration and licensing agreement with MSD (known as Merck in USA and Canada), to discover and develop novel immune-modulating therapies for cancer and autoimmune disorders.
In response to the ongoing outbreak of Ebola in Democratic Republic of the Congo, WHO with The Government of the Democratic Republic of Congo preparing to vaccinate high risk populations against Ebola virus disease.
Merck, known as MSD outside the United States and Canada, and Moderna Therapeutics announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA-based personalized cancer vaccines.
MSD (known as "Merck" in USA and Canada) announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.
Immutep, a leading Australian biotechnology company, announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of Immutep’s lead immunotherapy product
Eisai Co., Ltd. and MSD agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai.
Ferring Pharmaceuticals and MSD announced the completion of CHAMPION (Carbetocin Haemorrhage Prevention), a global clinical trial conducted by the Human Reproduction Program at the World Health Organization.
Merck and Viralytics Limited announced that the companies have signed a definitive agreement under which Merck will acquire Viralytics, an Australian company focused on oncolytic immunotherapy treatments for a range of cancers.
Companies’ financial success is often down to the strategic deals they are able to make with other pharmaceutical companies to enable them to develop the next leading drug in the market, observes GlobalData